Nigerian Doctor In U.S Leads Major Study On Antiviral Covid-19 Drug That Has Shown Promise [Video]

May 1, 2020
120 Views

U.S based Nigerian doctor, is leading a major study on an antiviral drug named ‘’ that appears to be effective in treating .

Dr Taiwo was interviewed by CNN and he explained the promising result of the drug in treating COVID-19 patients.

According to him, the preliminary results of Remdesivir shows that the drug can help hospitalised COVID-19 patients recover faster, but it does not significantly reduce death.

The US Food and Drug Administration has not yet approved any drugs for the treatment of the coronavirus. But it plans to announce an emergency-use authorization for remdesivir, according to The New York Times.

Watch the interview below:

[embedded content]
Subscribe to Kanyi TV
[embedded content]

KanyiDaily recalls that President Donald Trump had also approved the use of anti-malarial drug, Chloroquine, for the treatment of the coronavirus disease in the United States.

You may be interested

2024 CHANQ: History Not Kind To Us Against Ghana –Ogunmodede
Sports
1 views
Sports
1 views

2024 CHANQ: History Not Kind To Us Against Ghana –Ogunmodede

Webby - December 24, 2024

Home-based Super Eagles coach Daniel Ogunmodede says history has not been good to Nigeria when they face rivals Ghana.The home-based…

Ex-Chelsea Star Oscar Returns To Boyhood Club Sao Paulo
Sports
2 views
Sports
2 views

Ex-Chelsea Star Oscar Returns To Boyhood Club Sao Paulo

Webby - December 24, 2024

Former Chelsea midfielder Oscar is returning to his Brazilian boyhood club Sao Paulo after 14 years, which included a long…

‘I’m Incredibly Proud’– Arokodare Talks Up Genk’s Unbeaten Home Streak
Sports
1 views
Sports
1 views

‘I’m Incredibly Proud’– Arokodare Talks Up Genk’s Unbeaten Home Streak

Webby - December 23, 2024

Tolu Arokodare is full of excitement followingGenk’s historic victory over Anderlecht, reports Completesports.com.Sunday’s win at the Cegeka Arena was the…

Leave a Comment

Your email address will not be published.